Medical directoryActive ingredient
Tirzepatide
The first dual GIP and GLP-1 receptor agonist, given once weekly. Licensed in Spain for type 2 diabetes and for weight management.
Content reviewed by Dr. David Céspedes
Medical guides
Mounjaro before and after: what to expect month by month, according to the trials
ReadInsulin resistance: symptoms, how it is diagnosed and how to reverse it
ReadMounjaro reviews: what the trials show and what patients report
ReadHow much does Mounjaro cost per month in Spain: the real price per dose in 2026
ReadOrforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions
ReadObstructive sleep apnoea: what it is and how it is treated
ReadSurvodutide: what it is and where it currently stands
ReadWeight regain after stopping treatment: why it happens and how it is managed
ReadOrforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
ReadRetatrutide: what its phase 3 trial found, and why you can't get hold of it
ReadCagriSema: what it is, what the REDEFINE trials found and why it disappointed
ReadBuying Ozempic and Mounjaro in Spain: how to get them legally and safely
ReadGLP-1: what it is, how it works and why it is transforming obesity treatment
ReadMounjaro vs Ozempic: clinical differences, effectiveness and which one suits you
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.